ANIX - CIK 0000715446
Anixa Biosciences Inc (ANIX) reported revenue of $210.00K for fiscal year 2024, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2024 | $210.00K | +0.0% |
| FY 2023 | $210.00K | -59.0% |
| FY 2021 | $512.00K | +104.8% |
| FY 2019 | $250.00K | -77.5% |
| FY 2018 | $1.11M | +206.9% |
| FY 2017 | $362.50K | +20.8% |
| FY 2016 | $300.00K | -96.8% |
| FY 2015 | $9.26M | +152.4% |
| FY 2014 |
Between fiscal 2010 and fiscal 2024, Anixa Biosciences Inc's revenue declined from $730.67K to $210.00K.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $3.67M |
| +843.1% |
| FY 2013 | $388.85K | -58.6% |
| FY 2012 | $940.01K | -6.3% |
| FY 2011 | $1.00M | +37.3% |
| FY 2010 | $730.67K | - |